ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021
The global Alzheimer's Association round robin study on plasma amyloid β methods.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- Plasma biomarker strategies to reduce diagnostic uncertainty in p-tau217-based assessment of CSF amyloid positivity in secondary-care patients with MCI.Frontiers in aging neuroscience · 2026Article
- Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Article
- Clinical validation of a plasma-based antibody-free LC-MS method for identifying CSF amyloid positivity in mild cognitive impairment.Frontiers in aging neuroscience · 2025Article
- Homocysteine, neurodegenerative biomarkers, and APOE ε4 in neurodegenerative diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease.Alzheimer's research & therapy · 2024Article
- Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting.Molecular neurodegeneration · 2024Review
- Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings.Methods in molecular biology (Clifton, N.J.) · 2024Article
- More than microglia: myeloid cells and biomarkers in neurodegeneration.Frontiers in neuroscience · 2024Review
- ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Review
- Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer's disease.Clinical chemistry and laboratory medicine · 2023Article
- Annual stability of the plasma Aß40/42 ratio and associated factors.Annals of clinical and translational neurology · 2023Article
- Blood biomarkers for Alzheimer's disease in clinical practice and trials.Nature aging · 2023Review
- Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.Alzheimer's research & therapy · 2023Article
- Integrated partially linear model for multi-center studies with heterogeneity and batch effect in covariates.Statistics · 2023Article
- The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review.Alzheimer's research & therapy · 2022Review
- Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.CNS neuroscience & therapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 18 institutions in 8 countries.
Funding
Abstract
introductionBlood-based assays to measure brain amyloid beta (Aβ) deposition are an attractive alternative to the cerebrospinal fluid (CSF)-based assays currently used in clinical settings. In this study, we examined different blood-based assays to measure Aβ and how they compare among centers and assays.
methodsAliquots from 81 plasma samples were distributed to 10 participating centers. Seven immunological assays and four mass-spectrometric methods were used to measure plasma Aβ concentrations.
resultsCorrelations were weak for Aβ42 while Aβ40 correlations were stronger. The ratio Aβ42/Aβ40 did not improve the correlations and showed weak correlations. DISCUSSION: The poor correlations for Aβ42 in plasma might have several potential explanations, such as the high levels of plasma proteins (compared to CSF), sensitivity to pre-analytical sample handling and specificity, and cross-reactivity of different antibodies. Different methods might also measure different pools of plasma Aβ42. We, however, hypothesize that greater correlations might be seen in future studies because many of the methods have been refined during completion of this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.